-
Mirtazapine, a subsidiary of Minovar, passed the CDE technical review
Time of Update: 2022-04-27
On March 16, 2022, Minovar announced that its holding subsidiary Zhejiang Liaoyuan mirtazapine API has passed the CDE technical review, and the registration number will be displayed on the CDE API, ph
-
Financing in the pharmaceutical industry is frequent, focusing on cell therapy, ADC, genetic testing and other fields
Time of Update: 2022-04-26
AAV gene therapy new drug research and development company Jinweike recently completed a Pre-A round of financing of tens of millions of yuan .
On March 2, Huayi Lejian, a gene therapy drug research and development company, announced the completion of a series A financing of several hundred million yuan .
-
The list of 2022 Anhui smart factories and digital workshops is announced, and 10 pharmaceutical companies are on the list
Time of Update: 2022-04-26
It includes 10 enterprise projects in the pharmaceutical field, such as the modern Chinese medicine manufacturing intelligent factory project of Anhui China Resources Jinchan Pharmaceutical Co.
Freeze-dried Powder Injection Digital Workshop Anhui City Pharmaceutical Co.
-
More than 120 senior executives from nearly 100 pharmaceutical companies have resigned, including a large number of deputy general managers and core technicians
Time of Update: 2022-04-26
For example, in mid-February news, Buchang Pharmaceutical announced that the company received a written resignation report submitted by director and vice president Li Weijun .
On January 3, Huahai Pharmaceutical announced that the board of directors recently received the resignation document of Wang Jie, the vice president of the company.
-
The wave of mergers and acquisitions of chain pharmacies will continue, and these problems need to be solved urgently
Time of Update: 2022-04-26
It is reported that on March 7, the common people disclosed the announcement to terminate the acquisition of Huatuo Pharmacy's equity .
In addition to terminating the acquisition, on March 3, the common people also transferred 100% of the equity of Yifeng Xinxing Pharmacy Chain Hebei Co.
-
Domestic innovative drugs "going overseas" are injected with a shot of cardiac stimulant, and the future may be expected
Time of Update: 2022-04-26
Investors from Duoyao said that the approval of Legend Bio's CAR-T products by the FDA is another huge breakthrough for domestic innovative drugs, which greatly enhances the confidence of the industry .
According to the industry, the "going overseas" of innovative drugs is becoming a crucial breakthrough point for the development of domestic innovative drugs .
-
Fosun Pharma, Huahai Pharma Receive MMP License to Produce Generic Drugs of Novel Coronavirus Oral Drug Nematevir
Time of Update: 2022-04-26
On March 18, Fosun Pharma and Huahai Pharmaceutical announced separately that the MPP (Medicine Patent Pool Organization) granted them the use of related patents and know-how to produce generic drugs
-
Since 2022, 3 new drugs have been included in the list of priority review varieties
Time of Update: 2022-04-26
According to information from the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, since this year, three new drugs have been added to the list of priority review varieties, namely Boehringer Ingelheim (China)'s sebersolizumab injection, Shanghai Gumetinib tablets from Haihe Pharmaceutical Research and Development Co.
-
In order to accelerate the development and commercialization of innovative drugs, a large number of pharmaceutical companies are joining forces
Time of Update: 2022-04-26
Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients .
-
Alarm bells!
Time of Update: 2022-04-26
In addition, since the beginning of this year, many provincial food and drug administrations have announced the illegal behavior of pharmaceutical companies, involving many companies that have been punished by publicity for producing and selling inferior drugs.
-
Due to rising raw material prices, this traditional Chinese medicine company raised the price of its products twice in 3 months
Time of Update: 2022-04-26
According to a person familiar with Guangyuyuan: "Because the prices of raw materials for traditional Chinese medicines such as bezoar and musk have been rising in the past year, the prices have been raised .
-
Annual report disclosure season: A number of pharmaceutical equipment companies have obtained performance forecasts from securities companies and are expected to see strong performance growth
Time of Update: 2022-04-26
Pharmaceutical Equipment (Source: Pharmaceutical Network) Tofflon: Predicted net profit of 796 million yuan The data shows that as of March 16, 2022, a total of 7 institutions have made predictions on Tofflon's 2021 annual performance, including Industrial Securities, Guosheng Securities, China Merchants Securities, Zheshang Securities, CITIC Construction Investment, Essence Securities, Guohai Securities; Tofflon’s net profit is forecast to be 796 million yuan in 2021, a year-on-year increase of 71.
-
In February, the State Drug Administration approved a total of 198 registered medical device products
Time of Update: 2022-04-26
Recently, the State Drug Administration issued an announcement to announce the catalogue of medical device products approved for registration in February 2022 .
According to the medical device product catalog approved for registration in February 2022, Guangdong Baolight Medical Technology Co.
-
Roche's atezolizumab approved for perioperative adjuvant therapy in early stage lung cancer
Time of Update: 2022-04-26
The results of the IMpower010 study showed that in patients with stage II-IIIA NSCLC whose tumors expressed PD-L1 ≥1%, atezolizumab was used as adjuvant therapy after surgery and chemotherapy, compared with the current best treatment.
-
11 drugs approved for marketing! From Junshi Bio, Eli Lilly, Novo Nordisk, etc.
Time of Update: 2022-04-26
On March 14, CStone announced that the expanded indication of the RET inhibitor Pratinib (trade name: Pujihua) was successfully approved for marketing, and the product became the first approved product in China for RET mutant medullary thyroid cancer.
-
The three places have successively issued this notice, and the market of Chinese medicine decoction pieces may be deeply affected
Time of Update: 2022-04-26
For example, on March 10, the Shanxi Provincial Centralized Bidding and Purchasing Center for Pharmaceutical Equipment stated that in accordance with the requirements of the Sanming Procurement Alliance (National) Office's "Notice on Carrying out the Data Reporting Work for Some Varieties of Chinese Herbal Pieces", medical institutions in Shanxi Province were organized to carry out centralized collection of Chinese medicine pieces.
-
Qilu Pharmaceutical Risperidone Oral Dissolving Membrane Approved for Clinical Treatment of Mental Diseases
Time of Update: 2022-04-26
For patients who are effective in acute treatment, this product can continue to exert its clinical efficacy in maintenance treatment; adults and 10-17-year-old children and adolescents with bipolar disorder Disordered manic episodes; irritability associated with autism in children and adolescents aged 5-17 years; persistent aggression or other disruptive behaviors associated with mental retardation or mental retardation and conduct disorders in children and adolescents aged 5-17 years .
-
Asieris' diagnostic and postoperative monitoring drug Hikewei was approved by CDE to be included in the clinical real-world data application pilot
Time of Update: 2022-04-26
SH), a global innovative company focusing on urogenital tumors, recently announced that the Hainan Provincial Food and Drug Administration, based on the opinions of the Center for Drug Evaluation (CDE) of the State Drug Administration of China, has The drug Hexvix for bladder cancer diagnosis and postoperative monitoring was included in the pilot application of real-world data in drug clinical practice .
-
Seeking global development, a large number of pharmaceutical companies are going to Hong Kong to list
Time of Update: 2022-04-26
For example, a few days ago, Condini Pharmaceuticals, a pharmaceutical company focusing on rare diseases, submitted a prospectus to the Hong Kong Stock Exchange and plans to list in Hong Kong .
-
More than 20 pharmaceutical companies suspend drug transactions due to inability to produce or delist products
Time of Update: 2022-04-26
On March 16, the Guangzhou Public Resource Trading Center issued a notice on suspending the listing of some drugs on the Internet .
1) and the "Guangzhou Pharmaceutical Group's Procurement on the Internet Procurement Plan" ”, for drugs that cannot be produced normally, products are withdrawn from the market, etc.
